Financial Performance - The company's main business revenue has declined, particularly in mature hospitals in cities like Kunming, Chengdu, Wuhan, and Chongqing, with a slowdown in revenue and profit growth compared to the previous year[27]. - Management expenses and sales expenses as a percentage of operating income increased in 2022 compared to 2021, leading to a decline in overall profit[5]. - The net profit for the year significantly decreased due to complex domestic and international economic conditions and shrinking demand, despite the company's efforts to maintain stable operations[28]. - The financial report indicates a notable decrease in non-operating income, with other non-recurring gains and losses recorded at approximately ¥381,980[19]. - The company's total revenue for 2022 was approximately ¥1.73 billion, representing a year-on-year increase of 0.91%[47]. - Net profit attributable to shareholders decreased by 78.09% to CNY 20,568,200.89[64]. - The net profit after deducting non-recurring gains and losses was CNY 18,538,023.18, down 78.36% year-on-year[64]. - The gross profit margin for the medical sector was 41.65%, reflecting a decrease of 1.72% compared to the previous year[48]. Market Outlook - The company anticipates that the ophthalmic medical service industry will return to normal development as the economy gradually recovers, with previous investments and cost reduction efforts expected to yield results in the future[28]. - The Chinese ophthalmic medical service market is projected to reach RMB 223.1 billion by 2024, with a compound annual growth rate (CAGR) of 11.05% from 2020 to 2024[43]. - The number of myopic patients in China increased from 540 million in 2016 to 660 million in 2020, with the overall myopia rate rising from 39.2% to 47.1%[43]. - The cataract surgery market is expected to grow as awareness increases, with the incidence rate of cataracts in the population aged 60-89 at 80%[43]. Business Development - The company has established 24 chain ophthalmology specialty hospitals and is in the process of preparing several new hospitals, which are expected to drive future growth[45]. - The company is enhancing its medical technology and quality by recruiting renowned experts and improving medical quality management systems[45]. - The company is focusing on high-end surgical methods and multifunctional intraocular lenses to meet the quality demands of middle-aged and elderly patients[45]. - The company aims to improve its bargaining power with suppliers through scale expansion and centralized procurement, thereby reducing costs and increasing gross margin[45]. - The company has established a new regional division in the Greater Bay Area to enhance management efficiency and is focusing on this area as a key growth engine[46]. - The company is implementing a "national chain + local integration" strategy to enhance revenue growth potential[65]. Operational Efficiency - The company has completed organizational adjustments and optimizations to strengthen operational support across its national layout, which has resulted in increased personnel costs[5]. - The company has launched a stable and efficient HCRM system, currently operational in 9 hospitals, to improve management efficiency and service quality[58]. - The company aims to enhance its digital transformation and accelerate the construction of a digital development system[124]. - The company plans to enhance its data decision-making capabilities by accelerating the construction of a data center platform and integrating various digital systems[1]. Research and Development - Research and development investment amounted to ¥6,644,826.66, which is 0.39% of the operating revenue for 2022[83]. - The company is investing heavily in R&D, with a budget allocation of 100 million for new technologies and innovations[157]. - The company aims to establish a comprehensive medical education and research innovation system to promote product and service technology upgrades[148]. Governance and Management - The company has appointed new board members and management, including a new general manager, to strengthen governance and leadership[140]. - The governance structure has been enhanced to comply with regulatory standards, ensuring no significant discrepancies exist[156]. - The company is actively involved in the nomination process for board members and senior management, ensuring a robust governance structure[181]. - The company has established a clear decision-making process for the remuneration of directors, supervisors, and senior management, ensuring transparency and accountability[193]. Social Responsibility and Compliance - The company is actively responding to national calls and fulfilling corporate social responsibilities while focusing on strategic goals to enhance management efficiency[28]. - The company emphasizes maintaining high-quality medical services to mitigate risks associated with medical accidents[127]. - The company recognizes the potential impact of regulatory changes in the healthcare sector and is committed to adapting its strategies accordingly[151]. Customer and Market Engagement - The company has launched a member points mall to enhance member benefits and loyalty, providing various products and services for redemption[58]. - The company reported a significant increase in user data, with a year-over-year growth of 25% in active users[157]. - Major customers accounted for 6.86% of total annual sales, with the largest customer contributing 3.24%[51]. Financial Management - Cash flow from financing activities was CNY 1,038,322,980.00, a decrease of 2,445.05% compared to the previous year[58]. - The net increase in cash and cash equivalents was CNY 755,455,302.40, down 760.79% year-on-year[58]. - The company has a strong emphasis on internal controls and risk management, as highlighted by the independent director's expertise in these areas[186].

Financial Performance - The company's revenue for Q1 2023 was ¥649,826,753.50, representing a 38.73% increase compared to ¥468,422,199.36 in the same period last year[12]. - Net profit attributable to shareholders reached ¥162,393,315.01, a significant increase of 334.85% from ¥37,345,056.26 year-over-year[12]. - The basic earnings per share (EPS) was ¥1.09, up 230.30% from ¥0.33 in the previous year[12]. - The company's operating revenue for the reporting period was RMB 649.83 million, an increase of 38.73% compared to the previous period, primarily due to the expansion of new hospitals and increased sales scale[29]. - Net profit for the current period was ¥165,334,547.22, representing a substantial increase of 44.73% compared to ¥37,345,056.26 in the previous period[57]. - The company reported a basic and diluted earnings per share of ¥1.09, up from ¥0.33 in the previous period[57]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,129,697,823.92, reflecting a 12.31% increase from ¥3,676,965,643.95 at the end of the previous year[12]. - The total liabilities amounted to RMB 1.88 billion, compared to RMB 1.61 billion in the previous period[21]. - The total equity attributable to the parent company was RMB 2.23 billion, compared to RMB 2.07 billion in the previous period[21]. - Cash and cash equivalents at the end of the period totaled ¥932,964,231.47, up from ¥113,604,394.24 at the beginning of the period, reflecting a net increase of ¥6,734,399.75[51]. - The total assets at the end of the period reached $4.13 billion, up from $3.68 billion, indicating a growth of 12.2%[61]. - Non-current assets totaled $2.69 billion, up from $2.49 billion, representing an increase of 8.0%[61]. Cash Flow - The net cash flow from operating activities was ¥120,447,583.12, a slight decrease of 2.10% from the previous year[12]. - The net cash flow generated from operating activities was RMB 120.45 million, a decrease of 2.10% compared to the previous period, mainly due to increased costs[29]. - The net cash flow from operating activities was $120.45 million, slightly down from $123.03 million, a decrease of 2.1%[62]. - Cash outflow from investing activities was $209.01 million, compared to $265.09 million, showing a reduction of 21.1%[62]. - Cash inflow from financing activities was $182.80 million, down from $202.50 million, a decrease of 9.8%[62]. Expenses - Research and development expenses increased by 206.26% to ¥2,211,400.00, primarily due to increased spending on ophthalmology-related clinical applications and digital research[14]. - The company's management expenses for the reporting period were RMB 76.63 million, an increase of 12.42% compared to the previous period, primarily due to increased salaries and depreciation expenses[29]. - Total operating costs amounted to ¥549,611,128.83, up 30.94% from ¥419,861,898.34 in the prior period, primarily driven by a 40.04% increase in operating costs due to sales growth[38][59]. Acquisitions and Investments - The company completed the acquisition of 80% equity in Dongguan Guangming Eye Hospital[18]. - The company completed the acquisition of a 35% stake in Dongguan Guangming Eye Hospital, increasing its total ownership to 80%[45]. - The company's investment income for the reporting period was RMB 92.05 million, an increase of RMB 86.18 million compared to the previous period, mainly due to the revaluation of equity in Dongguan Guangming Eye Hospital[29]. Other Financial Metrics - The weighted average return on equity (ROE) improved to 7.56%, up from 3.86% in the previous year[12]. - The company experienced a 73.81% increase in taxes payable, primarily due to an increase in corporate income tax[14]. - The income tax expense for the current period was ¥23,978,782.96, a 46.39% increase from ¥16,379,916.00 in the previous period, mainly due to the increase in total profit[55]. - Other income increased to ¥2,418,412.98 from ¥1,646,244.94 in the previous period, indicating improved financial performance[38]. - The balance of goodwill at the end of the reporting period increased by 1440.08% compared to the beginning of the period, due to the conversion of an originally affiliated company into a non-same control enterprise[29]. - The balance of contract liabilities at the end of the reporting period increased by 45.07% compared to the beginning of the period, attributed to business scale growth[29]. - The balance of other payables at the end of the reporting period increased by 197.87% compared to the beginning of the period, due to increased operating expenses[29].

证券代码：301239 证券简称：普瑞眼科 公告编号：2023-039 成都普瑞眼科医院股份有限公司 关于举行2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院股份有限公司（以下简称"公司"）于2023年4月26日在 巨潮资讯网（www.cninfo.com.cn）披露公司《2022年年度报告》全文及摘要。 为便于广大投资者更加全面深入地了解公司经营管理情况，公司将于2023年5月 9日（星期二）15:00-17:00在全景网举办2022年度业绩说明会，本次年度业绩 说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次业绩说明会的人员有：公司董事长徐旭阳先生，独立董事汤华东 先生，副总经理兼董事会秘书金亮先生，财务负责人杨国平先生，保荐代表人 朱玉峰先生。 为进一步做好中小投资者保护工作，增进投资者对公司的了解，现就公司 2022年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议，提升交流效率和针对性。投 ...

证券代码：301239 证券简称：普瑞眼科 成都普瑞眼科医院股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |----------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | ...

证券代码：301239 证券简称：普瑞眼科 成都普瑞眼科医院股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |----------------|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | 投资者关系活动 | 特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 | | 中信建投：吴严；海通证券：余文心；海通证券：梁广楷、陈 | | 人员姓名 | | 铭；东北证券：刘宇腾、叶菁、古翰羲；华西证券：崔文亮、 程仲瑶；太平洋证券：盛丽华、 ...

成都普瑞眼科医院股份有限公司 2022 年第三季度报告 证券代码：301239 证券简称：普瑞眼科 公告编号：2022-045 成都普瑞眼科医院股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 成都普瑞眼科医院股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--- ...